In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overPharmaceutical / Industry112515
NCT00968968

Trial Description

Summary

This is a randomized, open-label, multi-center Phase III study evaluating the efficacy and safety of lapatinib in combination with trastuzumab versus trastuzumab alone as continued HER2 suppression therapy in women with HER2-positive metastatic breast cancer (MBC). Eligible subjects will have completed 12 to 24 weeks of first- or second-line treatment with trastuzumab plus chemotherapy, experienced either complete disappearance of all metastatic lesions, or persistence of metastatic disease (stable disease) without unequivocal progression or the occurrence of new lesions, and been indicated to continue to receive trastuzumab alone as maintenance therapy. Eligible subjects entering the LPT112515 study on first-line treatment will have no known history of central nervous system (CNS) metastases; subjects entering the study on second-line treatment will have no known history of CNS metastases or have stable (asymptomatic and off steroids ≥3 months) CNS metastases. The primary objective of this study is to compare progression-free survival (PFS) in subjects with HER2-positive MBC randomized to receive treatment with lapatinib plus trastuzumab versus those randomized to receive trastuzumab alone. The secondary objectives include overall survival, clinical benefit response rate (CR, PR or SD ≥24 weeks) and the qualitative and quantitative adverse event profile of the 2 treatment arms. It is estimated that 280 subjects (140 per group) will be required to observe 193 PFS events.

Eligibility Criteria

Inclusion Criteria:

  • Signed the informed consent form (ICF)
  • Female, ≥18 years of age
  • Histologically verified breast cancer with distant metastases (metastatic breast cancer)
  • Documentation of HER2 overexpression or gene amplification in the invasive component of either the primary tumor or metastatic disease site defined as:
  • 3+ by IHC and/or
  • HER2/neu gene amplification by fluorescence, chromogenic or silver in situ hybridization [FISH, CISH or SISH; >6 HER2/neu gene copies per nucleus or a FISH, CISH or SISH HER2 gene copies to chromosome 17 signal ratio of ≥2.0]
  • Completed 12 to 24 weeks of first- or second-line treatment with trastuzumab in combination with chemotherapy
  • Either complete disappearance of all lesions, or persistence of metastatic disease (stable disease) without unequivocal progression or the occurrence of new lesions
  • Documentation of lesion response during the course of therapy received prior to randomization (i.e., improvement or no worsening of tumor burden; the absence of new lesions)
  • Measurable disease is not required for study participation
  • No known or suspected (associated neurological signs and symptoms) brain metastases (including leptomeningeal involvement)
  • Stable brain metastasis (defined as asymptomatic and off steroids ≥3 months) are permitted in subjects entering LPT112515 on second-line treatment (completed 12-24 weeks of second-line treatment with trastuzumab plus chemotherapy)
  • Baseline of Left Ventricular Ejection Fraction (LVEF) ≥50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)
  • Completion of screening assessments (Refer to protocol for further details)
  • Have adequate marrow and organ function as defined in Table 2. Table 2 Laboratory Values SYSTEM LABORATORY VALUES Hematologic ANC ≥1.5 x 109/L Hemoglobin ≥9 g/dL (after transfusion if needed) Platelets ≥100 x 109/L Hepatic Albumin ≥2.5 g/dL Serum bilirubin ≤1.5 x ULN unless due to Gilbert's syndrome AST and ALT ≤3 x ULN Renal Calculated creatinine clearance* ≥ 40 mL/min Serum Creatinine ≤1.5 mg/dL or 132.6μmol/L *Calculated by the Cockcroft-Gault Equation (Refer to protocol for details) Abbreviations: ANC, absolute neutrophil count; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase

Exclusion Criteria:

  • History of other malignancy. Subjects who have been disease-free for 5 years or subjects with a history of completely resected non-melanoma skin cancer (basal or squamous) are eligible
  • Eastern Cooperative Oncology Group (ECOG) Performance Status >2
  • Concurrent anti-cancer treatment, except anti-hormonal therapy for subjects with hormone receptor positive breast cancer
  • Concurrent treatment with an investigational agent
  • Prior treatment with anti-HER2 therapy, except trastuzumab or lapatinib
  • Concurrent treatment with protocol-defined prohibited medications (refer to protocol for details)
  • Serious cardiac illness or medical condition including but not confined to:
  • Uncontrolled arrhythmias
  • Uncontrolled or symptomatic angina
  • History of congestive heart failure (CHF)
  • Myocardial infarction <6 months from study entry
  • Acute or current active (requiring anti-viral therapy) hepatic or biliary disease (with the exception of subjects with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  • Concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection or any psychiatric condition prohibiting understanding or rendering of informed consent)
  • Women of childbearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during the study treatment period. Adequate contraception includes intra-uterine device, barrier methods with spermicide, or oral contraceptives (unless clinically contraindicated for the subject population or per local practice, refer to protocol for further details)
  • Pregnant or lactating females
  • Any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study agents or their excipients that, in the opinion of the Investigator or GSK medical monitor , contra-indicates participation

Trial Contact Information

Trial Lead Organizations/Sponsors

GlaxoSmithkline

GSK Clinical TrialsStudy Director

US GSK Clinical Trials Call CenterPh: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com

Trial Sites

U.S.A.
Arizona
  Chandler
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Mesa
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Sedona
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
California
  Long Beach
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Los Angeles
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Georgia
  Augusta
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Illinois
  Highland Park
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Massachusetts
  Boston
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Missouri
  Columbia
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Montana
  Billings
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
North Carolina
  Raleigh
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Pennsylvania
  Abington
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Texas
  Garland
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Utah
  Bountiful
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Murray
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Salt Lake City
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Virginia
  Fairfax
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Gainesville
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Norfolk
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Virginia Beach
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
  Woodbridge
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Washington
  Tacoma
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Canada
Ontario
  Brampton
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com
Quebec
  Rimouski
 GSK Investigational Site
 US GSK Clinical Trials Call Center Ph: 877-379-3718
  Email: GSKClinicalSupportHD@gsk.com
 EU GSK Clinical Trials Call Center Ph: +44 (0) 20 8990 4466
  Email: GSKClinicalSupportHD@gsk.com

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00968968
ClinicalTrials.gov processed this data on October 17, 2013

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top